Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats. Longitudinal in vivo study

Spivak, Mykola; Bubnov, Rostyslav; Yemets, Ilya; Лазаренко, Л. М.; Timoshok, Natalia; Vorobieva, A. E.; Mohnatyy, Sergii; Ulberg, Z. R.; Reznichenko, L. S.; Grusina, T. G.; Жовнір, В. А.; Nm, Zholobak

doi:10.11152/mu.2013.2066.151.ms1ddc2

Cited by 18 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DOX (1 mg/kg/dose, intravenous [IV] injection) was given on 6 consecutive days and then once weekly for 6 weeks with a cumulative dose of 12 mg/kg, which has been consistently proven to be the maximal tolerated dose for rats. 42 Our pilot data show that this dose regimen led to significant tumor regression while producing substantial chronic cardiomyopathy, which allows a sufficient window to evaluate the effects of both antitumor efficacy and cardiotoxicity related to DOX chemotherapy. Animals were terminated 50 days after initiation of chemotherapy, a time window sufficient for animals to develop clinically and pathologically substantial cardiomyopathy and significant tumor regression.…”

Section: Experimental Methodsmentioning

confidence: 80%

Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω‐3 Polyunsaturated Fatty Acids

Xue

Denkinger

Schlotzer

et al. 2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Background Doxorubicin (DOX) has been one of the most effective antitumor agents against a broad spectrum of malignancies. However, DOX-induced cardiotoxicity forms the major cumulative dose-limiting factor. Glutamine and ω-3 polyunsaturated fatty acids (PUFAs) are putatively cardioprotective during various stresses and/or have potential chemosensitizing effects during cancer chemotherapy. Methods Antitumor activity and cardiotoxicity of DOX treatment were evaluated simultaneously in a MatBIII mammary adenocarcinoma tumor-bearing rat model treated with DOX (cumulative dose 12 mg/kg). Single or combined treatment of parenteral glutamine (0.35 g/kg) and ω-3 PUFAs (0.19 g/kg eicosapentaenoic acid and 0.18 g/kg docosahexaenoic acid) was administered every other day, starting 6 days before chemotherapy initiation until the end of study (day 50). Results Glutamine alone significantly prevented DOX-related deterioration of cardiac function, reduced serum cardiac troponin I levels, and diminished cardiac lipid peroxidation while not affecting tumor inhibition kinetics. Single ω-3 PUFA treatment significantly enhanced antitumor activity of DOX associated with intensified tumoral oxidative stress and enhanced tumoral DOX concentration while not potentiating cardiac dysfunction or increasing cardiac oxidative stress. Intriguingly, providing glutamine and ω-3 PUFAs together did not consistently confer a greater benefit; conversely, individual benefits on cardiotoxicity and chemosensitization were mostly attenuated or completely lost when combined. Conclusions Our data demonstrate an interesting differentiality or even dichotomy in the response of tumor and host to single parenteral glutamine and ω-3 PUFA treatments. The intriguing glutamine × ω-3 PUFA interaction observed draws into question the common assumption that there are additive benefits of combinations of nutrients that are beneficial on an individual basis.

show abstract

Section: Experimental Methodsmentioning

confidence: 80%

Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω‐3 Polyunsaturated Fatty Acids

Xue

Denkinger

Schlotzer

et al. 2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…Current paper is the follow-up of the previous works by the group [4,17,48,49,51,59,72], and it arises many essential multidisciplinary issues for obesity complications, and related conditions to be adopted in clinical set to yield safer, more effective, and expensive medical interventions with higher value [76]. These results provide a basis for more in-depth studies of the Fenugreek effects potential for the prevention and treatment of obesity-related diseases and managing patients with CKD holistically.…”

Section: Consolidation Of the Pppm Conceptmentioning

confidence: 99%

“…There has been a progressive increase in studies using mouse models of renal disease vs the use of rats [28,50]. Several models addressed to collateral diseases consider cardiovascular parameters in the development renal injury [51][52][53]. The use of HFD in the C57BL/6 mouse is a suitable model to induce whole body and metabolic effects commonly seen in the human MetS and is associated with renal damage likely to lead to progressive renal disease [54].…”

Section: Reliable Obesity Animal Modelsmentioning

confidence: 99%

Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model—comparative study

et al. 2017

View full text Add to dashboard Cite

Background Worldwide obesity spread is a global health problem and needs to be further studied. Co-morbidities of obesity include insulin resistance, diabetes mellitus type 2, and dyslipidemia, which are the most frequent contributing factors for metabolic syndrome (MetS), as well as nonalcoholic fatty liver disease and chronic kidney disease. The aim was to study renal function and endogenous intoxication panel on high-calorie diet-induced obesity rat model and perform comparative study of the treatment efficacy of Fenugreek-based bionanocomposite vs antiobesogenic drugs (Orlistat). Materials We included 60 male rats and equally divided them to 6 groups of 10 animals in each group: the experimental groups were firstly assigned as controls and high caloric diet (HCD)-fed groups, and each group further was subdivided to remain untreated, Fenugreek bionanocomposite (BNC)-treated, and Orlistat-treated. Normal control rats (groups 1, 2, 3) were fed by a standard chow, while the others (groups 4, 5, 6) were fed with HCD ad libitum during 98 days. From days 77 to 98, groups 2 and 5 were treated with BNC based on Fenugreek (150 mg/kg body weight, orally) and groups 3 and 6 were treated with antiobesogenic drug Orlistat (10 mg/kg body weight, orally). Food and water consumptions were measured daily and body weights were measured once a week. On day 99, blood was collected; the creatinine, urea, and uric acid were estimated in serum according to the standard protocols. Levels of low and middle molecules (MMs) were measured; the quantity of oligopeptides was estimated by Bradford method. We performed the liver and kidney ultrasonography in rats.Results We revealed an increase in the levels of endogenous intoxication syndrome markers (MM and oligopeptides) in all animals with experimental obesity. Ultrasound data showed injury of the liver and kidneys in obese rats. We observed significant decreasing of MM levels after Orlistat treatment vs controls (p < 0.05). However, this effect was more pronounced in Fenugreek BNC-treated group vs both Orlistattreated and controls (p < 0.05). Orlistat treatment evoked rising of serum creatinine and oligopeptides in control animals

show abstract

“…The suggested optimal cardiotoxic dose of doxorubicin for extended and longitudinal observation of rats has not been determined [109]. …”

Section: Reviewmentioning

confidence: 99%

“…( C ) Mild ascites in a rat. A strip of liquid is revealed near the liver - an indirect sign of venous congestion in a large circulation [109]. …”

Section: Reviewmentioning

confidence: 99%

Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application

Spivak

Bubnov

Yemets³

et al. 2013

EPMA Journal

View full text Add to dashboard Cite

The article overviews the potential biomedical applications of nanoscale gold particles for predictive, preventive and personalised nanomedicine in cardiology. The review demonstrates the wide opportunities for gold nanoparticles due to their unique biological properties. The use of gold nanoparticles in cardiology is promising to develop fundamentally new methods of diagnosis and treatment. The nanotheranostics in cardiovascular diseases allows the non-invasive imaging associated with simultaneous therapeutic intervention and predicting treatment outcomes. Imaging may reflect the effectiveness of treatment and has become a fundamental optimisation setting for therapeutic protocol. Combining the application of biomolecular and cellular therapies with nanotechnologies foresees the development of complex integrated nanodevices. Nanocardiology may challenge existing healthcare system and economic benefits as cardiovascular diseases are the leading cause of morbidity and mortality at present.

show abstract

Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats. Longitudinal in vivo study

Cited by 18 publications

References 16 publications

Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω‐3 Polyunsaturated Fatty Acids

Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω‐3 Polyunsaturated Fatty Acids

Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model—comparative study

Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application

Contact Info

Product

Resources

About